Download PDF (71.5
Total Page:16
File Type:pdf, Size:1020Kb
JOBNAME: Seville PAGE: 1 SESS: 3 OUTPUT: Thu Sep 22 12:18:24 2016 Index abuse of dominant position Community Trade Mark 374–5 collecting societies 467–8 design proprietor’s rights 247–8 exhaustion of rights 453 domain names 373–4 IPR and competition conflicts 457–8 audiovisual performances prohibitions Beijing Treaty 20–22 within internal market 483–4 free transferability 20–21 pharmaceutical products 495–501 Australia 155, 157, 210, 264–5, 380, 382 refusal to supply or license on reasonable authors terms 484–93 joint authorship 45 standard essential patents 493–5 resale rights 89–91 advertising comparative or misleading Belgium 8, 10, 44 definition 368–9 Berne Convention harmonisation 367–71 background 9–10 parallel imports 402–4 challenges 15 trade marks, use of another’s in 436–40 databases 47–8 aircraft, design right exclusions 252 exclusive rights 11 animals independence of protection 10–11 geographical indications 387 moral rights 11–12, 15 patent exclusions national treatment 9–10 biological resources 165–71, 201, 204–6 resale rights 88 Onco-mouse 165–6, 176–7, 182–3 term of protection 12, 16, 18, 44–5 supplementary protection certificates three step test 11, 16, 20, 30, 38, 49 (SPCs) 193–9 biological diversity active ingredients 194–9 Convention 114–15, 118–23, 202–3 infringement vs. disclosure test 196–7 definition 118 product, definition 196–8 biological resources term 199 access and benefit-sharing 120–22 anti-competitive practices patents 1, 104, 118–23 assignments 459–60 discoveries vs. inventions 154–7 block exemptions 462–3, 477–83 DNA/human biological material 155–7, co-promotion agreements 477 178–83, 201, 204 collecting societies 467–71 exclusions 109–10 dual pricing 472–6 geographical origins 115, 201 licensing agreements 460–67 germ line therapy 182, 204 passing off 217, 339, 342, 372, 377, 504 human cloning 180–81, 204 pharmaceutical industry 472–83 human embryos and stem cells 179–82, reverse-payment patent settlements 476–7 204 technology transfer block exemptions isolated biological material 155–7, 202–3 462–3, 477–83 morality exclusions 175–83, 201–4 unilateral action 472 Onco-mouse 165–6, 176–7, 182–3 appellations of origin 340, 377–9 plants and animals 165–71, 201, 204–6 artists biopiracy 114–15 resale rights 89–91 Biosafety Clearing-House 120–21 assignment Biotechnology anti-competitive practices 459–60 Cartagena Protocol 120 521 Catherine Seville - 9781781003480 Downloaded from Elgar Online at 09/26/2021 03:02:14AM via free access Columns Design XML Ltd / Job: Seville-EU_Intellectual_Property_Law_and_Policyxxx / Division: Index /Pg. Position: 1 / Date: 22/9 JOBNAME: Seville PAGE: 2 SESS: 2 OUTPUT: Thu Sep 22 12:18:24 2016 522 EU intellectual property law and policy Directive 102, 200–207 European Licensing Passport 93–5 CBD and TRIPS, interaction with 202–3 exhaustion of rights 421–2 compulsory licensing 206 freedom to provide services 96 exclusions 201–6 multi-territorial licensing 95 farm saved seed 205–6 purpose 93–5 human cloning 204 colours, as trade marks 276–7, 285 human embryos and stem cells 204 common law systems 7, 23 morality exclusions 201–4 common origin doctrine 413–17 plants and animals 167–9, 204–6 Community Plant Variety Right 211–16 reporting requirements 207 effects of 215–16 block exemptions 462–3, 477–83 procedures 212–13 bootlegging 13–14, 19–20 validity criteria 213–15 border measures 512–13 Community Trade Mark Customs Action Plan 507–8 applications 269–73 destruction of goods 514–15 assignment 374–5 exclusions 514 background 268–9 Regulation 513–15 cancellation 342–53 small consignments procedures 515 absolute grounds 343–5 brands bad faith 342–5 trade marks, compared 259–60 generic marks 351–2 Brazil 116, 445 invalidity 342–6 broadcasting misleading marks 352–3 copyright non-use 346–51 1984 Green Paper 39 relative grounds 346 cable retransmission 40–42 revocation 346–53 digital technology 42–3 classification of goods and services 270, licensing 39, 464–7 376 rental rights 37–8, 40 defences Rome Convention 13–14 descriptive uses 363–4 Satellite and Cable Directive 39–43 exhaustion of right 366–7 TRIPS Agreement 16 national law to prevent use of WIPO Treaties 15 Community Trade Mark 366 Brussels Regulation 515–19 use of own name and address 362–3 business identifier trade marks 339–42 use to indicate intended purpose 364–6 business methods patents 161–2 Directive 268–9 examinations 271 Canada 380 free movement 416 car spare parts, design protection 4 geographical indications 295–6, 340–41 Certificates of Complementary Protection 193 harmonisation China 380, 507 comparative or misleading advertising cinematographic works see films 367–71, 376 civil law systems 7, 23 domain names 372–4 civil proceedings unfair commercial practices 371–2 enforcement of IPR 503–4 infringement 353–5, 361–2 jurisdiction, Brussels Regulation 515–19 guarantee of origin function 358–61 cloning 180–81, 204 use in course of trade 356–8 collecting societies 467–71 intention to use mark 271 collective management organisations (CMOs) invalidity, grounds for 312 93–6 languages 269–70 collective rights management licensing 374–5 competition conflicts 468–71 objects of property 374–5 conflicts 95–6 Office for Harmonization in the Internal Directive 93–7 Market (OHIM) 262, 269 Catherine Seville - 9781781003480 Downloaded from Elgar Online at 09/26/2021 03:02:14AM via free access Columns Design XML Ltd / Job: Seville-EU_Intellectual_Property_Law_and_Policyxxx / Division: Index /Pg. Position: 2 / Date: 15/9 JOBNAME: Seville PAGE: 3 SESS: 2 OUTPUT: Thu Sep 22 12:18:24 2016 Index 523 opposition proceedings 272–3 sounds 273, 275, 277–8 overview 268–9 registration criteria 273–81 publication 272 renaming 376 purpose 268–9, 361–2, 416 renewal 268 reform proposals 375–7 searches 271–2 refusal, absolute grounds 271, 281–312, service marks 280–81 376 term of protection 268 acquired distinctiveness 297–300 transactions involving 374–5 bad faith 312 comparative advertising see advertising customary and generic marks 296–7 competition deceptive marks 310–11 abuse of dominant position descriptive marks 291–6 collecting societies 467–8 geographical names 295–6 exhaustion of rights 453 non-distinctiveness 271, 279, 282–90 within internal market 483–4 non-verbal marks 299–300 IPR conflicts 457–8 public interest 287–8 pharmaceutical products 495–501 public policy and morality 308–10 refusal to supply or license on reasonable shape exclusions 300–307 terms 484–93 special emblems prohibited by law standard essential patents 493–5 311–12 anti-competitive practices refusal, relative grounds 271, 312–42, assignments 459–60 376 block exemptions 462–3, 477–83 business identifiers and earlier rights co-promotion agreements 477 339–42 collecting societies 467–71 detriment to earlier mark 331–3 dual pricing 472–6 detriment to reputation of earlier mark licensing agreements 460–67 333–4 pharmaceutical industry 472–83 geographical indications 340–41 reverse-payment patent settlements global appreciation 315–16 476–7 identical goods and services 314–15 technology transfer block exemptions identical trade marks 313–15 462–3, 477–83 likelihood of confusion 314–27 unilateral action 472 marks with a reputation 327–31 copyright licensing practices 463–7 similar goods and services 315–16, IPR, conflicts between 323–4 exhaustion of rights 453 similar trade marks 315–23 existence vs. exercise of rights 407–8, unfair advantage of earlier mark 334–9 458 registrable marks 3, 273–81 pharmaceutical products cases 398–404, capable of distinguishing 279, 282–90 406–7 colours 276–7, 285 reasons for 457–9 compound marks 283–4 parallel imports 398–404, 425–6 decorative elements 283 repackaging/relabelling 398–402 descriptive marks 291–6 artificial market partitioning 426–7 geographical names 295–6 competition conflicts 398–402 graphic representation 274–9, 287 condition of product, impacts on 427 letters and numbers 284 damage to reputation 428 names 288–9 necessity 430–34 positional marks 288 pharmaceutical products 398–402, service marks 280–81 424–36 shapes 279, 284–8, 300–307 prior notice 428–9 signs 273–4 responsibility indications 427–8 slogans 289–90 Trade Marks Directive 425–32 smells and tastes 275–6 see also free movement Catherine Seville - 9781781003480 Downloaded from Elgar Online at 09/26/2021 03:02:14AM via free access Columns Design XML Ltd / Job: Seville-EU_Intellectual_Property_Law_and_Policyxxx / Division: Index /Pg. Position: 3 / Date: 15/9 JOBNAME: Seville PAGE: 4 SESS: 2 OUTPUT: Thu Sep 22 12:18:24 2016 524 EU intellectual property law and policy computer programs secondary infringement 29 copyright WIPO Treaties 18 adequate protection measures 18–19 databases anti-tampering remedies 19 Berne Convention 47–8 decompilation 30 controversies 50–51 Directive 27–33 Directive 47–57 EU Green Paper 1988 25–6 information monopolies 50–51 exceptions 29–30 information re-utilisation 55–6 exhaustion of rights 30–32, 420 intellectual creation criteria 49 resale rights 31–3 substantial investment criteria 48–9, 52–5 secondary infringement 29 sui generis right 49–57 WIPO Treaties 18 TRIPS Agreement 16–17 international exhaustion of rights 454 Digital Agenda 17–19, 98–9 patents 152, 157–65 Digital Single Market 2, 5, 43, 98–101 European Patent Convention 129 digital technology 6, 8, 17–19 confidence, breach of 217, 236, 248 E-Commerce Directive 57–61 trade secrets (proposed Directive) 519 distribution rights 18 Convention on Biological Diversity 118–23 Information Society Directive 62, 70–74 access and benefit-sharing 120–22 EU regime advance